Zai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer TranscriptSeeking Alpha · 2 days ago
Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer StudyMarketBeat · 2 days ago
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung CancerBusiness Wire · 2 days ago
Zai Lab Announces $250 Million Private PlacementBusiness Wire · 3 days ago
Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026Business Wire · 4 days ago
Zai Lab Limited Unsponsored ADR (ZLAB) – What Are Brokerages Thinking About This Stock?Defense World · Oct 18, 2026Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.68 | -$0.46 | Beat |
| May 7, 2026 | -$0.53 | -$0.46 | Beat |
| Feb 26, 2026 | -$0.44 | -$0.46 | Miss |
| Nov 6, 2025 | -$0.28 | -$0.33 | Miss |
| Aug 7, 2025 | -$0.37 | -$0.37 | Beat |
| May 8, 2025 | -$0.50 | -$0.45 | Beat |